GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Syneos Health Inc (FRA:8IN) » Definitions » Debt-to-EBITDA

Syneos Health (FRA:8IN) Debt-to-EBITDA : 7.40 (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Syneos Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Syneos Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €63 Mil. Syneos Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €2,609 Mil. Syneos Health's annualized EBITDA for the quarter that ended in Jun. 2023 was €361 Mil. Syneos Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 7.40.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Syneos Health's Debt-to-EBITDA or its related term are showing as below:

FRA:8IN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.42   Med: 5.68   Max: 22.82
Current: 6.26

During the past 12 years, the highest Debt-to-EBITDA Ratio of Syneos Health was 22.82. The lowest was 2.42. And the median was 5.68.

FRA:8IN's Debt-to-EBITDA is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 1.875 vs FRA:8IN: 6.26

Syneos Health Debt-to-EBITDA Historical Data

The historical data trend for Syneos Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syneos Health Debt-to-EBITDA Chart

Syneos Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.13 6.16 6.22 4.89 4.50

Syneos Health Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.25 3.81 5.60 54.50 7.40

Competitive Comparison of Syneos Health's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Syneos Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syneos Health's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Syneos Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Syneos Health's Debt-to-EBITDA falls into.



Syneos Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Syneos Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(64.187 + 2672.33) / 608.069
=4.50

Syneos Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(63.017 + 2609.276) / 361.336
=7.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.


Syneos Health  (FRA:8IN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Syneos Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Syneos Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Syneos Health (FRA:8IN) Business Description

Traded in Other Exchanges
N/A
Address
1030 Sync Street, Morrisville, NC, USA, 27560-5468
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Syneos Health (FRA:8IN) Headlines

No Headlines